Details

Autor(en) / Beteiligte

• Hattori, Yosuke
• Kojima, Toshihisa
• Kaneko, Atsushi
• Kida, Daihei
• Hirano, Yuji
• Fujibayashi, Takayoshi
• Yabe, Yuichiro
• Oguchi, Takeshi
• Kanayama, Yasuhide
• Miyake, Hiroyuki
• Kato, Takefumi
• Takagi, Hideki
• Hayashi, Masatoshi
• Ito, Takayasu
• Shioura, Tomone
• Takahashi, Nobunori
• Ishikawa, Hisato
• Funahashi, Koji
• Ishiguro, Naoki

Titel

High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab

Ist Teil von

• Modern rheumatology, 2018-01, Vol.28 (1), p.119-125

Ort / Verlag

United States: Taylor & Francis

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Objective: This study aimed to determine whether serum matrix metalloproteinase-3 (MMP-3) levels can predict remission in rheumatoid arthritis (RA) patients treated with adalimumab (ADA). Methods: Subjects were 114 RA patients continuously treated with ADA for 52 weeks. Predictive factors at baseline and 4 weeks after initiation of ADA therapy for the achievement of remission (28-point count Disease Activity Score-CRP (DAS28-CRP) < 2.3) at 52 weeks were evaluated by multivariate logistic regression analysis. Results: DAS28-CRP at 4 weeks (odds ratio (OR) 0.614, 95% confidence interval (CI) 0.382-0.988) and improvement in serum MMP-3 levels at 4 weeks (OR 1.057, 95% CI 1.002-1.032) were independent predictors of remission at 52 weeks. The best cut-off level of DAS28-CRP and improvement in serum MMP-3 levels at 4 weeks for predicting remission at 52 weeks was 3.73 (sensitivity: 90%, specificity: 50%, area under the receiver operating characteristic curve (AUC): 62%) and 39.93% (sensitivity: 47%, specificity: 83%, AUC: 64%), respectively. Conclusion: Our findings suggest that a high rate of improvement in serum MMP-3 levels at 4 weeks after initiation of ADA therapy can predict remission at 52 weeks in RA patients.